

May 28-29, 2018 London, UK

Graham Wilfred Ewing, J Healthc Commun 2018, Volume 3 DOI: 10.4172/2472-1654-C1-004

STRANNIK IS THE FIRST MEDICAL TECHNOLOGY TO Incorporate an understanding of how the Brain Regulates the Body's function





CEO, Mimex Montague Healthcare Limited, Mulberry House, 6 Vine Farm Close, Cotgrave, Nottingham NG12 3TU, United Kingdom

Ctrannik cognitive software is based upon a mathematical Omodel of how the brain regulates the autonomic nervous system and physiological systems. It comprises the screening technology Strannik Virtual Scanning (SVS) and the therapeutic modality Strannik Light Therapy (SLT). SVS is a Point of Care technology which identifies the most destabilised physiological system(s), organ(s) and cellular morphology for each organ; provides a summary of the ca 15 pathologies in each of the 30 main organs; the extent of genotype and phenotype for each of the ca 15*30 reported pathologies; and the onset of pathologies from their presymptomatic onset. Initial research has illustrated that SVS performs 2-23% more accurately than the range of diagnostic tests against which it was compared. Published peer-reviewed papers have illustrated the scope of SVS as an advanced screening technique which can more effectively screen the complex pathological correlates of all common medical conditions including diabetes, cardiovascular disease, alzheimer's disease, migraine, raynaud's phenomenon, etc. It has also been shown to be of value in a predictive capacity e.g. to illustrate susceptibility to heart attack, stroke, migraine, etc. SLT uses the data from the Strannik test to define the parameters of a biofeedback-type technique which acts by re-establishing the coherent function of the autonomic nervous system and physiological systems. Initial research has indicated a 75-96% level of effectiveness depending upon the nature of the condition to be treated. It has been shown to be particularly effective treating sleeping and breathing disorders, migraine, dyslexia, etc.

Biography

Graham Wilfred Ewing graduated from Northumbria University with B.Sc. Chemistry. In 2003 he started working with the Strannik technology. Over the period 2003-2018 he has authored ca 80 peer-reviewed medical papers and conference presentations in his efforts to illustrate the scientific and medical significance and value of the Strannik technology which was developed by Dr Igor Grakov. Mr Ewing is currently CEO Mimex Montague Healthcare Limited.

14th Edition of International Conference on

Health & Primary Care

egraham.ewing@mmhcl.co.uk